Related Experiment Video

Updated: Apr 19, 2026

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty
10:03

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty

Published on: January 28, 2020

6.0K

Prognostic Benefit of Beta-blockers After Acute Coronary Syndrome With Preserved Systolic Function. Still Relevant

Sergio Raposeiras-Roubín1, Emad Abu-Assi1, Alfredo Redondo-Diéguez1

  • 1Servicio de Cardiología, Hospital Clínico Universitario de Santiago de Compostela, Santiago de Compostela, A Coruña, Spain.

Revista Espanola De Cardiologia (English Ed.)
|December 17, 2014
PubMed

Insights

Beta-blockers significantly reduce long-term mortality in acute coronary syndrome patients with preserved ejection fraction. This finding supports their continued use in this specific patient group.

Area of Science:

  • Cardiology
  • Pharmacology
  • Clinical Research

Background:

  • Existing evidence on beta-blockers post-acute coronary syndrome (ACS) predates modern revascularization techniques and often focuses on patients with impaired ventricular function.
  • The prognostic benefit of beta-blockers in ACS patients with preserved left ventricular ejection fraction (LVEF) requires current validation.

Purpose of the Study:

  • To evaluate the current long-term prognostic value of beta-blocker therapy in patients experiencing acute coronary syndrome (ACS) who have preserved left ventricular ejection fraction (LVEF).

Main Methods:

  • Retrospective cohort study involving 3236 ACS patients with LVEF ≥ 50%.
  • Propensity score matching created comparable groups (555 patients each) with and without beta-blocker treatment.
  • Cox regression analysis assessed the association between beta-blockers and mortality during follow-up.

Main Results:

  • Over a median of 5.2 years, 506 patients (15.6%) died.
  • Beta-blocker treated patients (n=2277) exhibited significantly lower mortality (11.6% vs 25.2%, P<.001).
  • Post-matching, beta-blocker use remained associated with reduced mortality (14.4% vs 18.9%, P=.020) and was an independent protective factor (HR=0.64, P=.004).

Conclusions:

  • Beta-blocker treatment is linked to reduced long-term mortality in acute coronary syndrome patients with preserved left ventricular ejection fraction.
  • These findings support the use of beta-blockers as a beneficial long-term strategy for this specific ACS population.
Abstract

Keywords:
Acute coronary syndromeBeta-blockersBloqueadores betaMortalidadMortalitySíndrome coronario agudo

More Related Videos

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing12:45

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing

Published on: December 11, 2017

11.1K
Evaluation of Coronary Flow Reserve After Myocardial Ischemia Reperfusion in Rats06:32

Evaluation of Coronary Flow Reserve After Myocardial Ischemia Reperfusion in Rats

Published on: June 28, 2019

8.6K

Related Concept Videos

Heart Failure Drugs: &#946;-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
1.2K
Adrenergic Antagonists: Pharmacological Actions of &#946;-Receptor Blockers01:27

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in...
2.0K
Antihypertensive Drugs: Types of &#946;-Blockers01:28

Antihypertensive Drugs: Types of β-Blockers

β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and...
2.0K
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
484
Adrenergic Antagonists: &#593; and &#946;-Receptor Blockers01:31

Adrenergic Antagonists: ɑ and β-Receptor Blockers

Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
1.4K
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
503